Zimmer Biomet has seen a strong operating performance despite years of stagnation, making its shares compelling. The company's valuation has become more reasonable, with revenues trending at around...

Zimmer Biomet (ZBH) is working to strengthen its foothold in emerging markets that provide long-term opportunities for growth.

Zimmer Biomet (ZBH) gains from solid strategic execution and increasing traction in innovations in the third quarter.

Zimmer Biomet (ZBH) came out with quarterly earnings of $1.65 per share, beating the Zacks Consensus Estimate of $1.59 per share. This compares to earnings of $1.58 per share a year ago.

Zimmer Biomet Holdings Inc on Tuesday beat Wall Street estimates for third-quarter profit, as a rebound in knee surgeries lifted demand for the medical device maker's products.

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zimmer Biomet (ZBH) is expected to have witnessed strong performance across Avenir Complete hip.

Zimmer Biomet (ZBH) plans to work on the overall shift of the company's legacy knee systems to a fully rounded-out Persona portfolio.

Zimmer Biomet Holdings outlined strategies to gain market share in the knee sector and foster innovation in hip products. ZBH has raised its 2023 growth forecast, reflecting confidence in its strat...

Zimmer Biomet (ZBH) is benefiting from increased provider capacity, resulting in backlog pull-through in the recent quarters.

Zimmer Biomet Holdings, Inc. has experienced a selloff alongside the healthcare sector in H2 FY'23. Despite the recent downturn, the company still represents compelling long-term value in my view. ...

Health Care sector ETF (XLV) has underperformed the S&P 500 by 15 percentage points but has shown a modest revival in the last month. Zimmer Biomet had a solid earnings report and raised its 2023 r...